Close

Anti-MDM2 DNA-encoded mAb (DMAb), pVAX1 (DMAb-2112-FY)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This product is the plasmid containing an encoded anti-MDM2 DMAb sequence. The plasmid can drive transcription and in vivo translation of the desired antibody.

  Add to Cart

Specifications

  • Target
  • MDM2
  • Vector Name
  • pVAX1
  • Vector Description
  • pVAX1 was originally designed for the development of DNA vaccines. Its eukaryotic DNA sequences limited to the expression of desired sequence so that minimize the possibility of chromosomal integration. This vector has been widely used for the construction of DMAb plasmid.
  • Vector Promoter
  • CMV
  • Vector Tag or Fusion
  • Untagged
  • Delivery Method
  • Transfection
  • Cloning Method
  • Restriction Enzyme ⁄ MCS
  • Constitutive or Inducible System
  • Constitutive
  • Storage
  • Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term.
  • Background
  • DNA-encoded mAb (DMAb) technology is a novel approach for a direct in vivo production of desired biologically active immunoglobulins according to the plasmid DNA delivery into tissue where the delivered plasmid containing an encoded antibody sequence. Compared with the traditional mAb, DMAb can be functionally equivalent with additional advantages such as expression profiles, glycosylation, as well as no reliance on in vivo tissue culture and costly or time-consuming production systems. The DMAb technology may provide a novel, simple, less frequent, cost-effective approach for therapeutics.

Target

  • Entrez Gene ID
  • 4193
Sub CAT. DMAb Clone DMAb Host Target Species DMAb Isotype DMAb Immunogen  
DMAb-2112-FY CBFYM-0323 Mouse Human IgG2a Synthetic peptide, conjugated to KLH, corresponding to residues 389-402 of human MDM2
DMAb-2113-FY CBFYM-0419 Mouse Human IgG1
DMAb-2114-FY CBFYM-0613 Mouse Human
DMAb-2115-FY CBFYM-1955 Mouse Human IgG1 Human recombinant protein fragment corresponding to amino acids 119-438 of human MDM2 (NP_002383) produced in E.coli
DMAb-2116-FY CBFYM-1956 Mouse Human IgG2a Synthetic peptide conjugated to KLH, corresponding to amino acids 389-402 of Human MDM2. Epitope: The epitope recognized by the antibody is localized in the C-terminal region of MDM2 (amino acids 389-402 of human MDM2)
DMAb-2117-FY CBFYM-1957 Mouse Human IgG2b E. coli-derived recombinant human MDM2/HDM2, Asn3-Pro491
DMAb-2118-FY CBFYM-1958 Mouse Human IgG2a Synthesized peptide of human MDM2 (AA: ASEQETLVRPKPLLc)
DMAb-2119-FY CBFYM-1959 Mouse Human IgG2b, k A synthetic peptide derived from human MDM2 protein (1)
DMAb-2120-FY CBFYM-1960 Mouse Human IgG1, k Recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
DMAb-2121-FY CBFYM-1961 Mouse Human IgG2b, k Synthetic peptide corresponding to the N-terminal of human MDM2
DMAb-2122-FY CBFYM-1962 Mouse Human IgG1 Synthetic peptide, CSRPSTSSRRRAISE, corresponding to amino acids 154-167 of human MDM2
DMAb-2123-FY CBFYM-1963 Rabbit Human IgG Recombinant protein corresponding to amino acids 215-422 of human MDM2
DMAb-2124-FY CBFYM-1964 Mouse Human IgG1 KLH conjugated synthetic peptide encompassing a sequence within the N-term region of human MDM2
DMAb-2125-FY CBFYM-1965 Mouse Mouse IgG1 Recombinant mouse MDM2

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-MDM2 DNA-encoded mAb (DMAb), pVAX1 (DMAb-2112-FY). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.